A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2018
At a glance
- Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer; Liver cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Mar 2018 Planned End Date changed from 18 Dec 2020 to 20 Feb 2020.
- 27 Mar 2018 Planned primary completion date changed from 18 Dec 2019 to 7 Feb 2019.